Compare iShares MSCI China ETF (MCHI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs ResMed Inc. — how do they compare? iShares MSCI China ETF trades at $55.05, while ResMed Inc. trades at $224.92 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while iShares MSCI China ETF pays none, and ResMed Inc. is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | RMD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $293.73 |
52-Week Low | $50.48 | $182.82 |
Market Cap | — | $32.61B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $55.2, down 3.04% over the past day. Technical indicators show a bullish overall signal with strong moving average support, while oscillators are neutral. The ETF is positioned near key support at $55. Recent news highlights China's strong export growth, particularly in AI and tech sectors, and institutional interest, though some funds have reduced holdings. A dividend of $0.36 per share is scheduled for payment in June 2026.
The outlook for MCHI is cautiously optimistic, driven by China's robust export performance and tech sector strength, but tempered by geopolitical tensions and regulatory risks. Investment opportunities include exposure to undervalued Chinese equities and AI-driven growth, while risks involve U.S.-China trade friction and potential economic slowdowns. Investors should weigh these factors against the ETF's current technical strength.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
